Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy'

Pathompong Thongsan/iStock via Getty Images Silence Therapeutics plc (NASDAQ:SLN) develops RNA interference ("RNAI") therapies that silence genes associated with various diseases. SLN employs its proprietary mRNAi GOLD platform to produce short interfering RNAs (siRNAs) that degrade disease-related mRNA. It focuses especially on genes expressed in the liver, which is an ideal target due to its essential role in metabolism and regulating proteins, fats, and carbohydrates. Currently, SLNCF's main drug candida ...